GatifloxacinThird Party Manufacturing in India

Gatifloxacin works by inhibiting two essential bacterial enzymes — DNA gyrase and topoisomerase IV. DNA gyrase is responsible for introducing negative supercoils into bacterial DNA, allowing proper replication and transcription. Topoisomerase IV is involved in separating replicated chromosomal DNA during bacterial cell division. By binding to these enzyme-DNA complexes, gatifloxacin prevents the re-ligation of DNA strands, leading to double-strand breaks and ultimately bacterial cell death.

As a fourth-generation fluoroquinolone, gatifloxacin exhibits enhanced activity against both gram-positive and gram-negative bacteria compared to earlier generation quinolones. The 8-methoxy group on its quinolone ring contributes to its improved activity against resistant strains and reduces the likelihood of resistance development. Gatifloxacin is particularly effective against respiratory pathogens including Streptococcus pneumoniae, Haemophilus influenzae, and atypical organisms like Mycoplasma pneumoniae and Chlamydia pneumoniae. Its dual inhibition of both DNA gyrase and topoisomerase IV makes it difficult for bacteria to develop resistance through single-point mutations.

Therapeutic Uses

Gatifloxacin is prescribed for the treatment of various bacterial infections:

• Acute Bacterial Exacerbation of Chronic Bronchitis: Effective against common respiratory pathogens including S. pneumoniae and H. influenzae
• Community-Acquired Pneumonia: Used for mild to moderate CAP, including cases involving atypical pathogens
• Acute Sinusitis: Indicated for bacterial sinusitis caused by susceptible organisms
• Bacterial Conjunctivitis: Ophthalmic formulations (0.3% and 0.5% solutions) are widely used for eye infections

Why Manufacturers Choose Gatifloxacin

Gatifloxacin third party manufacturing in India has been a significant segment of the antibiotic production market. Despite the FDA withdrawal of systemic gatifloxacin in 2006 due to dysglycemia concerns, the molecule continues to find substantial use in ophthalmic applications and in several international markets where its risk-benefit profile is considered acceptable. Indian WHO-GMP certified manufacturers produce gatifloxacin tablets (400mg) and ophthalmic solutions for both domestic and export destinations.

The molecule offers versatility in manufacturing, with both oral tablet formulations and sterile ophthalmic preparations being commercially viable. For PCD franchise operators, gatifloxacin presents an opportunity particularly in the ophthalmic segment where demand remains steady.